Idiopathic Hypersomnia Severity Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Idiopathic hypersomnia severity scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Idiopathic Hypersomnia Severity Scale Today - Breaking & Trending Today

Low-sodium Oxybate Improves Idiopathic Hypersomnia Symptoms, Even Sleep Inertia

Low-sodium oxybate treatment may improve sleep inertia via changes in VAS-SI scores, for patients with idiopathic hypersomnia. ....

United States , American Academy Of Neurology , Idiopathic Hypersomnia Severity Scale , Epworth Sleepiness Scale , Patient Global Impression ,

Zevra Highlights Plans to Advance IH, Narcolepsy Drug Candidate

Zevra reported progress in 2023, including results from a phase 2 study for idiopathic hypersomnia and plans to expand into narcolepsy. ....

Neilf Mcfarlane , Drug Administration , Zevra Therapeutics Inc , Investigational New Drug , Therapeutics Inc , Epworth Sleepiness , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Brain Fog ,

KP1077 Is Safe, Tolerable for Improving Idiopathic Hypersomnia Symptoms

A phase 2 trial found KP1077 provides clinically meaningful benefits for idiopathic hypersomnia. ....

United States , Christopher Drake , Henry Ford Health Christopher Drake , American Academy Of Sleep Medicine , Drug Administration , Us Drug Enforcement Agency , Henry Ford Health , Zevra Therapeutics , American Academy , Orphan Drug Designation , Enforcement Agency , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Epworth Sleepiness , Brain Fog Severity Scale , Therapeutics Announces Top Line Data , Global News , Kind Indication , Chronic Sleep Disorder , Accessed March , Idiopathic Hypersomnia , Sleep Problems , Excessive Sleepiness ,

Zevra Reports Positive Phase 2 Results for IH Drug Candidate

Zevra Therapeutics announced positive topline results from its phase 2 clinical trial evaluating KP1077 for idiopathic hypersomnia (IH). ....

Putilich Dreamstime , Christopher Drake , Neil Mcfarlane , Drug Administration , Zevra Therapeutics , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Brain Fog ,

Zevra Therapeutics Announces Top-Line Data from the Phase 2

KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study . ....

United States , Christopher Drake , Neil Mcfarlane , Nichol Ochsner , Ignacio Guerrero Ros , Adannag Alexander , Zevra Therapeutics Inc , Us Drug Enforcement Agency , Drug Administration , Exchange Commission , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Principal Investigator , Chief Executive Officer , Brain Fog , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Nasdaq Zvra , Zevra Therapeutics ,